Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
The immune status of ovarian cancer patients receiving anti-CA125 murine monoclonal antibody B43.13 was evaluated by measuring antiidiotypic antibodies (Ab2), antiantiidiotypic antibodies (Ab3), antiisotypic human antimouse antibodies (HAMA), interferon-gamma, and CA125 levels in the serum. A specific assay was developed for the determination of Ab2 antibodies using chimeric MAb B43.13. Of the 50 patients studied, 26 had elevated levels of Ab2. Eleven of these 26 patients also had high titer of antiantiidiotypic (Ab3) antibodies. Eight of the 22 patients analyzed had increased interferon-gamma levels. A tentative correlation was found between survival of these patients' antiidiotype induction.
Madiyalakan
R
R
Biomira Research Inc., University of Alberta, Edmonton, Canada.
Sykes
T R
TR
Dharampaul
S
S
Sykes
C J
CJ
Baum
R P
RP
Hör
G
G
Noujaim
A A
AA
D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis* / Q000097:blood / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen / Q000276:immunology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy; D012189:Retrospective Studies
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen; C107428:oregovomab